Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Live Attenuated Vaccines Market

ID: MRFR/Pharma/0595-HCR
110 Pages
Satyendra Maurya
Last Updated: April 15, 2026

Live Attenuated Vaccines Market Research Report Information, By Type (Bacterial, Viral), By Vaccine Development (Tissue Culture, Embryonated Eggs, Live Animals) and End Users (Hospitals, Clinics, Diagnostic Centers, Research Institute, Others) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Live Attenuated Vaccines Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type (USD Billion) | |
      1. 4.1.1 Bacterial Vaccines | |
      2. 4.1.2 Viral Vaccines |
    2. 4.2 Healthcare, BY Vaccine Development (USD Billion) | |
      1. 4.2.1 Tissue Culture | |
      2. 4.2.2 Embryonated Eggs | |
      3. 4.2.3 Live Animals |
    3. 4.3 Healthcare, BY End Users (USD Billion) | |
      1. 4.3.1 Hospitals | |
      2. 4.3.2 Clinics | |
      3. 4.3.3 Diagnostic Centers | |
      4. 4.3.4 Research Institutes | |
      5. 4.3.5 Others |
    4. 4.4 Healthcare, BY Region (USD Billion) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Sanofi (FR) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Merck & Co. (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 GlaxoSmithKline (GB) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Pfizer (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Bristol-Myers Squibb (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 AstraZeneca (GB) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Novartis (CH) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Johnson & Johnson (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Takeda Pharmaceutical Company (JP) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    8. 6.5 US MARKET ANALYSIS BY END USERS |
    9. 6.6 CANADA MARKET ANALYSIS BY TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    11. 6.8 CANADA MARKET ANALYSIS BY END USERS |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY TYPE |
    14. 6.11 GERMANY MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    15. 6.12 GERMANY MARKET ANALYSIS BY END USERS |
    16. 6.13 UK MARKET ANALYSIS BY TYPE |
    17. 6.14 UK MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    18. 6.15 UK MARKET ANALYSIS BY END USERS |
    19. 6.16 FRANCE MARKET ANALYSIS BY TYPE |
    20. 6.17 FRANCE MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    21. 6.18 FRANCE MARKET ANALYSIS BY END USERS |
    22. 6.19 RUSSIA MARKET ANALYSIS BY TYPE |
    23. 6.20 RUSSIA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    24. 6.21 RUSSIA MARKET ANALYSIS BY END USERS |
    25. 6.22 ITALY MARKET ANALYSIS BY TYPE |
    26. 6.23 ITALY MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    27. 6.24 ITALY MARKET ANALYSIS BY END USERS |
    28. 6.25 SPAIN MARKET ANALYSIS BY TYPE |
    29. 6.26 SPAIN MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    30. 6.27 SPAIN MARKET ANALYSIS BY END USERS |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY END USERS |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY TYPE |
    36. 6.33 CHINA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    37. 6.34 CHINA MARKET ANALYSIS BY END USERS |
    38. 6.35 INDIA MARKET ANALYSIS BY TYPE |
    39. 6.36 INDIA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    40. 6.37 INDIA MARKET ANALYSIS BY END USERS |
    41. 6.38 JAPAN MARKET ANALYSIS BY TYPE |
    42. 6.39 JAPAN MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    43. 6.40 JAPAN MARKET ANALYSIS BY END USERS |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY END USERS |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY TYPE |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY END USERS |
    50. 6.47 THAILAND MARKET ANALYSIS BY TYPE |
    51. 6.48 THAILAND MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    52. 6.49 THAILAND MARKET ANALYSIS BY END USERS |
    53. 6.50 INDONESIA MARKET ANALYSIS BY TYPE |
    54. 6.51 INDONESIA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    55. 6.52 INDONESIA MARKET ANALYSIS BY END USERS |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY TYPE |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY END USERS |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY TYPE |
    61. 6.58 BRAZIL MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    62. 6.59 BRAZIL MARKET ANALYSIS BY END USERS |
    63. 6.60 MEXICO MARKET ANALYSIS BY TYPE |
    64. 6.61 MEXICO MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    65. 6.62 MEXICO MARKET ANALYSIS BY END USERS |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY TYPE |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY END USERS |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USERS |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USERS |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USERS |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY TYPE |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY VACCINE DEVELOPMENT |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY END USERS |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    90. 6.87 HEALTHCARE, BY VACCINE DEVELOPMENT, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY VACCINE DEVELOPMENT, 2024 TO 2035 (USD Billion) |
    92. 6.89 HEALTHCARE, BY END USERS, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY END USERS, 2024 TO 2035 (USD Billion) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USERS, 2025-2035 (USD Billion) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END USERS, 2025-2035 (USD Billion) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END USERS, 2025-2035 (USD Billion) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END USERS, 2025-2035 (USD Billion) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END USERS, 2025-2035 (USD Billion) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END USERS, 2025-2035 (USD Billion) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END USERS, 2025-2035 (USD Billion) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END USERS, 2025-2035 (USD Billion) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END USERS, 2025-2035 (USD Billion) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END USERS, 2025-2035 (USD Billion) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END USERS, 2025-2035 (USD Billion) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END USERS, 2025-2035 (USD Billion) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END USERS, 2025-2035 (USD Billion) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END USERS, 2025-2035 (USD Billion) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END USERS, 2025-2035 (USD Billion) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END USERS, 2025-2035 (USD Billion) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END USERS, 2025-2035 (USD Billion) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END USERS, 2025-2035 (USD Billion) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END USERS, 2025-2035 (USD Billion) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END USERS, 2025-2035 (USD Billion) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END USERS, 2025-2035 (USD Billion) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END USERS, 2025-2035 (USD Billion) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END USERS, 2025-2035 (USD Billion) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END USERS, 2025-2035 (USD Billion) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END USERS, 2025-2035 (USD Billion) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END USERS, 2025-2035 (USD Billion) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END USERS, 2025-2035 (USD Billion) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END USERS, 2025-2035 (USD Billion) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY VACCINE DEVELOPMENT, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END USERS, 2025-2035 (USD Billion) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Bacterial Vaccines
  • Viral Vaccines

Healthcare By Vaccine Development (USD Billion, 2025-2035)

  • Tissue Culture
  • Embryonated Eggs
  • Live Animals

Healthcare By End Users (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Research Institutes
  • Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions